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INTRODUCTION
The leading cause of the disorder of lactose digestion is the 
discrepancy between the level of lactose load and the activ-
ity of lactase production. Single nucleotide polymorphisms 
(SNP) of the lactase gene (LCT) affect the characteristics 
of the production of this enzyme during human ontogen-
esis. According to modern concepts, at position 13910 of 
the LCT gene sequence, the majority of representatives of 
the human population have cytosine (C). This cytosine 
base is located approximately 14 kb upstream of the LCT 
transcription site, in the regulatory region of the lactase 
gene - MCM6 (minichromosome maintenance complex 
6). The gradual age-related decrease in the level of lactase 
production, most often manifested from the second year 
of life, is characteristic of the individual’s homozygous state 
(C/C). The homozygous state of C/C 13910 is recorded in, 
more than 32% of Caucasians, 99% of East Asians, 74% of 
South Asians and 59% of individuals of other or mixed 
ethnic groups [1]. The loss of the lactase activity of the 
lactase and the ability to synthesize lactase at a sufficiently 
high level throughout life is characteristic of individuals 
with the SNP of the LCT gene, which are characterized 
by replacement of the cytosine by the thymine base (T) at 
position 13910. The SNP data of the LCT gene lead to the 
appearance two variants of genotypes: heterozygous (C/T) 
and homozygous (T/T). Taking into account, that allele T 
is dominant; both these genotypes are accompanied by 
lactase persistence (LP) [2; 3; 4; 5].
The maximum level of LCT expression is noted in the 
duodenum (121.7 RPKM (reads per kilobase per million), 
and the jejunum (73.8 RPKM) and provides hydrolysis of 
lactose disaccharide to two monosaccharides - glucose 
and galactose, capable of being absorbed by intestinal 
enterocytes [6]. Galactose is metabolized in the liver, 
where epimerization to glucose occurs upon accession 
to uridine-5’-diphosphate (UDP), with the formation of 
UDP-glucose. UDP-glucose is a direct precursor of glyco-
gen synthesis and can not be reversed through UDP-glu-
cose pyrophosphorylase (EC 2.7.7.9) to glucose-1-phos-
phate in vivo [7]. Due to this pathway, which is perhaps 
one of the evolutionary advantages of galactose as a lactose, 
almost 100% of the dietary galactose absorbed from the 
gastrointestinal tract, is converted into hepatic glycogen. 
While with lactase deficiency (LD), it becomes impossible.
Most often clinical manifestations of LD begin to be 
registered from 10 to 16 years of age, which coincides with 
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the HOMA-IR index in the two comparison groups. 
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the critical period of risk of obesity and the formation of 
insulin resistance in the pubertal period. It is in adolescents 
12-19 years, the incidence of obesity has the highest level 
- 20.5%, while in the children’s population as a whole, this 
figure is about 17% [8, 9, 10].
It is also interesting that the occurrence of LP in the geo-
graphical regions of Europe has a negative feedback from 
the prevalence of obesity. Thus, the maximum frequency 
of occurrence of LP, more than 90%, is observed among 
the population of the Nordic countries of Scandinavia and 
the Netherlands, and the minimum among the population 
of southern Europe (Italy and Spain). The lowest preva-
lence of overweight and obesity in the European Region 
is registered in Norway and is 15% among children aged 
7- 8 years (13.5% for boys and 17.8% for girls), the highest 
level is in Italy and is 36% (among boys – 37.2% and among 
girls – 34.7%) [11]. Therefore, we believe that the genotype 
C/C 13910, associated with adult-type LD, is targeted for 
the emergence of a systemic inflammatory response and 
the formation of insulin-resistant obesity [12].
The occurrence of obesity and its complicated course in 
recent years, especially among children living in large cit-
ies, is increasing at an epidemic rate, but the causes of this 
pathomorphosis remain poorly understood. In particular, 
the role of lactose in the formation of insulin resistance 
associated with obesity in children is not reflected.
THE AIM
Objective: to study associations between obesity and gen-
otype C/C 13910 of the lactase gene (LCT) in children, 
to investigate the effectiveness of treatment using drug 
exogenous lactase and a low-lactose diet.
MATERIALS AND METHODS
We inform that patients gave their informed consent 
to participate in the study. The study was carried out 
according to the ethical principles of the Medical Study 
conducted with the participation of people set forth in the 
Helsinki Declaration. The study was with the permission 
of the local bioethics commission in accordance with the 
requirements of the bioethical committee (protocol No. 2 
of the bioethical examination of the State Institution “DMA 
of Ministry of Health of Ukraine” dated 10.02.2016. Head 
of the Commission: MD, Professor V.V. Koldunov).
Genotyping was carried out at the polymorphic locus 
of the LCT gene by real-time polymerase chain reaction 
(RT-PCR) in 70 obese children and 40 healthy children 
from 6 to 18 years of age. The SNP LCT study was carried 
out in a certified Synevo laboratory, as the analyzer used 
the detector “CFX96 (BioRad)”, USA. The material for the 
study was venous blood.
To determine insulin resistance, the Homeostasis Model 
Assessment was calculated, before and after treatment, based on 
basal insulinemia and blood glucose in venous blood, using the 
Immunochemical Test Method with Electrochemiluminescent 
Detection (ECLIA) in the Synevo laboratory. The presence of 
insulin resistance was recorded with the index HOMA-IR>95th 
percentile, respectively, with the percentile curves recommend-
ed by the IDEFICS consortium for the European population 
according to the age and sex of the child [13].
A hydrogen breath test with lactose load (at a rate of 
1 g/kg but not more than 25 g of lactose in the form of 
a 10% aqueous solution) was performed at the “Gastro+ 
Gastrolyser” Gas Analyzer of the British company “Bed-
font Scientific Ltd” at the Institute of Gastroenterology of 
the National Academy of Medical Sciences of Ukraine. 
The hydrogen concentration in the patient’s exhaled air 
was determined in parts per million (ppm). The test was 
considered positive when the level of hydrogen concen-
tration in the exhaled air increased by more than 20 ppm 
(0.002%) after 60 minutes compared to the basal level and 
the appearance of clinical symptoms of LD during the next 
three hours of observation [14]. An increase of H2 in air 
samples without the appearance of characteristic symptoms 
indicated the lactose maldigestion, with the appearance 
of characteristic symptoms - of lactose intolerance [15].
Children with obesity, with genotype C/C 13910 and 
lactose maldigestion (n=40), to study the effectiveness of 
various treatments, were randomized in two comparison 
groups. Patients from group I (n=20) received an exog-
enous lactase preparation “Mamalac” (National Enzyme 
Company Inc., USA, Distributor in Ukraine: Pharmunion 
BSV Development Ltd.), 30 mg (3000 ALU Aspergillus 
orizae) three times a day for 1 month, and patients in 
group II (n=20) had a low-lactose diet, according to the 
computer program ,,Low- lactose diet” [16]. In addition, all 
patients and their parents received counseling on lifestyle 
modification, psychologist’s recommendations, in the case 
of insulin resistance; children over 12 years of age were 
prescribed metformin at the age-appropriate dosage.
Criteria for the effectiveness of treatment were the nor-
malization of the HOMA-IR index and HBT indices.
Statistical processing of the results of the study used the 
methods of variation statistics using the STATISTICA 
software package (version 6.1) StatSoftInc. serial number 
AGAR 909E415822FA, adapted for biomedical research 
with the False Discovery Rate control (FDR) to compare 
the effectiveness of various methods of treatment (p<0.05).
RESULTS
Insert the text of the results here. In children with obesity 
of 6-18 years (n=70), the genotype C/C 13910 was reg-
istered in 57.1% (n=40), the genotype of C/T 13910 - in 
28.6% (n=20), and the genotype T/T 13910 - in 14.3% of 
cases (n=10). Of 40 healthy children 6-18 years old, the 
genotype C/C 13910 was registered in 37.5% (n=15), the 
genotype of C/T 13910 was 55% (n=22), and the genotype 
T/T 13910 - in 7.5% of cases (n=3).
The level of hydrogen concentration in the exhaled air, de-
termined using the HBT in obese children and with genotype 
C/C 13910 was 36.03±3.71 ppm; in children with genotype 
T/T 13910 – 1.35±0.83 ppm; and in healthy children with gen-
otype C/C 13910 – 14.21±3.54 ppm, p<0.05. It is interesting 
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that the level of hydrogen concentration in the exhaled air with 
HBT in healthy children with genotype C/C 13910 did not 
have a statistical difference compared to obese children with 
the genotype C/T 13910– 21.51±3.1 ppm (p>0.05).
It was identified that a high level of HOMA-IR index 
of 5.97±0.86 was recorded in children with obesity and 
genotype C/C 13910. With the C/T 13910 genotype, the 
HOMA-IR index level was 4.17±0.21 and was lower than in 
genotype C/C 13910 (p<0.05). The lowest HOMA-IR index 
was characteristic of children with obesity and genotype 
T/T 13910 – 3.16±0.66 (p<0.05), figure 1.
The fact that the level of HOMA-IR index in 
children with obesity and genotype T/T 13910 was 
comparable to that of healthy children (HOMA-IR 
index=2.24±0.51, p>0.05) is of great interest. Probably, 
this circumstance emphasizes the special role of lactase 
deficiency in the development of insulin resistance in 
children’s obesity.
The study of the effect of diet and pharmacological 
therapy on insulin resistance in obese children showed 
that both methods of treatment are quite effective. Thus, in 
children of group I, before the prescription of the drug for 
exogenous lactase, the value of the HOMA-IR index was 
7.36±0.34, and after one month of treatment they had a 
significant decrease in 1.85 times, up to 3.97±0.6 (p<0.05). 
In children of group II, the HOMA-IR index before treat-
ment was 5.55±0.68, and after the administration of the 
low-lactose diet for one month its value decreased by 1.75 
times and was 3.16±0.35 (p<0.05).
DISCUSSION
Insert the text of the discussion here. The genotype of C/C 
13910 in children with obesity aged from 6 to 18 years is 2 
times more common than in children with physiological 
body weight. According to HBT data, the highest frequency 
of lactose maldigestion is registered among children with 
genotype C/C 13910, which coincides with the results of 
other studies [9]. According to the literature, the value of 
the correlation coefficient between the determination of 
genotype C/C 13910 by genotyping SNP LCT and the prob-
ability of a positive HBT is 0.74 [17]. Concetta Santonocito 
et al. [18] demonstrated that in persons with positive HBT 
genotype C/C 13910 was determined in 97% of cases. Our 
study showed that the ratio between the levels of the hy-
drogen breath test in 70 children with obesity and different 
genotypes of T/T, C/T, C/C 13910 corresponds to 1:16:27. 
It follows that in children with obesity and genotype C/C 
13910, the risk of lactose maldigestion is 27 times higher 
than in T/T 13910 genotype. Changes in the results of HBT, 
which occurred as the consequence of treatment, indicate 
that the use of exogenous lactase “Mamalac” (National 
Enzyme Company Inc., USA, Distributor in Ukraine: 
Pharmunion BSV Development Ltd.) and a low-lactose 
diet according to our computer program “Low-lactose 
diet” significantly (p<0.05) contribute to lactose digestion 
in patients with genotype C/C 13910.
Excess lactose in the diet of modern man causes clinical 
manifestations of lactase deficiency. Food interviewing 
conducted by Lucyna Ostrowska et al. [19] showed that 
clinical lactase persistence in adult males correlates with a 
low HOMA-IR index. Studies Priska Stahel et al. [20] have 
shown that in male Sprague-Dawley rats, eating a diet that 
contains 15% galactose increases insulin sensitivity, and the 
use of higher doses of galactose promotes the formation 
of type 2 diabetes.
In our study, the level of insulin resistance studied by 
calculating the HOMA-IR index was directly correlated 
Figure 1. Association figures hydrogen concentration in exhaled air in a HBT and insulin resistance in obese children with genotypes LCT
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with the level of lactose maldigestion in obese children 
and was the highest in the genotype of C/C 13910, which 
is identical to the data of other authors [21].
The ratio of HOMA-IR index in children with T/T, C/T, 
C/C 13910 genotypes was 1:1,3:2. It is likely that the risk 
of insulin resistance in children with obesity and genotype 
C/C 13910 is 2 times higher than in genotype T/T 13910. 
It is possible that the deficiency of lactase is accompanied 
by the interaction of excess lactose with galectin 9 (Gal-9), 
which blocks it binding to the Tim-3 receptor and prevents 
the activation of signaling pathways that activate Treg - cells. 
Inhibition of the Gal-9/Tim-3 signaling pathway leads to the 
development of a low-level inflammatory response and, as 
a consequence, to the formation of insulin resistance [11].
The use of an exogenous lactose drug or a low-lactose 
diet in treating children with genotype C/C 13910 and 
obesity, approximately, equally contributes to a decrease in 
the level of insulin resistance. It should be noted that the 
administration of exogenous lactase preparations preserves 
the possibility of taking dairy products, so necessary in the 
childhood period.
CONCLUSIONS
In this study, we demonstrated for the first time the sig-
nificance of lactose maldigestion associated with genotype 
C/C 13910 LCT, when insulin resistance is formed in obese 
children. The genotype of C/C 13910 is 2 times more often 
detected in obese children than in healthy children and is 
associated with lactose maldigestion, causing an increase in 
insulin resistance (p<0.05). The use of the drug exogenous 
lactase or low-lactose diet prevents the formation of insu-
lin resistance in children with obesity and genotype C/C 
13910 LCT. However, being aware of the fact, that dairy 
products are the source of other nutrients, we recommend 
prescribing exogenous lactase preparations especially for 
young children.
In the future, it is planned to study the effect of lactose 
maldigestion on the level of expression of the main ligand 
of the T-cell apoptosis receptor (Tim-3) of galectin 9 in 
children with obesity and genotype C/C 13910.
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